Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Single-center, Open-label, Single-arm Clinical Study to Observe the Safety and Efficacy of CM355 in the Treatment of Refractory Systemic Lupus Erythematosus

Next Previous
Trial Profile

A Single-center, Open-label, Single-arm Clinical Study to Observe the Safety and Efficacy of CM355 in the Treatment of Refractory Systemic Lupus Erythematosus

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 29 Jun 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CM 355 (Primary)
  • Indications Systemic lupus erythematosus
  • Focus Adverse reactions

Most Recent Events

  • 22 Jun 2026 According to Prolium Bioscience media release, the company announces the completion of the last patient, last visit in a 26-week investigator-initiated study of PRO-203 in treatment-refractory lupus nephritis (LN) patients. Data from the LN study will be shared at an upcoming medical meeting.
  • 22 Jun 2026 Status changed to active, no longer recruiting as per Prolium Bioscience media release
  • 11 Aug 2025 New trial record

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top